2337. Immunogenicity and Safety of a Heterologous Booster Dose of Omicron Subvariant (BA.1 and BA.5) and Bivalent SARS-CoV-2 Recombinant Spike Protein Vaccines: A Phase 3, Randomized, Clinical Trial

BACKGROUND: Currently circulating Omicron subvariants contain mutations permitting evasion of neutralization with prototype vaccines. Novel Omicron BA.1 (NVX-CoV2515) and Omicron BA.5 (NVX-CoV2540) subvariant-specific vaccines were tested alone or as bivalent preparations combined with the prototype...

Descripción completa

Detalles Bibliográficos
Autores principales: Bennett, Chijioke, Woo, Wayne, Marcheschi, Alex, Mallory, Raburn M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679145/
http://dx.doi.org/10.1093/ofid/ofad500.1959

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679145/
http://dx.doi.org/10.1093/ofid/ofad500.1959

Ejemplares similares